Catalyst
Slingshot members are tracking this event:
In Q4 2017, Opko (OPK) to commence Phase 2b trial to test TT701 (OPK88004) ability to reduce prostate size, increase muscle mass and bone strength, and decrease fat mass in men with enlarged prostate (BPH)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| OPK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 27, 2017
Occurred Source:
http://investor.opko.com/releasedetail.cfm?ReleaseID=1049844
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Tt701, Enlarged Prostate, Bph, Phase 2b
